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ABSTRACT 
Background & Aims Recent studies suggest that heparins reduce liver fibrosis and the risk of decompensation of liver 
disease. Here, we evaluated the effects of enoxaparin in several experimental models of advanced cirrhosis. Methods 
Cirrhosis was induced in male Sprague‐Dawley (SD) rats by: (i) Oral gavage with carbon tetrachloride (CCl4ORAL), (ii) Bile 
duct ligation (BDL) and (iii) CCl4 inhalation (CCl4INH). Rats received saline or enoxaparin s.c. (40 IU/Kg/d or 
180 IU/Kg/d) following various protocols. Blood biochemical parameters, liver fibrosis, endothelium‐ and fibrosis‐related 
genes, portal pressure, splenomegaly, bacterial translocation, systemic inflammation and survival were evaluated. 
Endothelial dysfunction was assessed by in situ bivascular liver perfusions. Results Enoxaparin did not ameliorate liver 
function, liver fibrosis, profibrogenic gene expression, portal hypertension, splenomegaly, ascites development and 
infection, serum IL‐6 levels or survival in rats with CCl4ORAL or BDL‐induced cirrhosis. Contrarily, enoxaparin worsened 
portal pressure in BDL rats and decreased survival in CCl4ORAL rats. In CCl4INH rats, enoxaparin had no effects on hepatic 
endothelial dysfunction, except for correcting the hepatic arterial dysfunction when enoxaparin was started with the CCl4 
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exposure. In these rats, however, enoxaparin increased liver fibrosis and the absolute values of portal venous and sinusoidal 
resistance. Conclusions Our results do not support a role of enoxaparin for improving liver fibrosis, portal hypertension or 
endothelial dysfunction in active disease at advanced stages of cirrhosis. These disease‐related factors and the possibility of 
a limited therapeutic window should be considered in future studies evaluating the use of anticoagulants in cirrhosis. 
ABBREVIATIONS 
  Acta2   smooth muscle alpha‐2 actin  
  BDL   bile‐duct ligation  
  BW   body weight  
  CCL4INH   carbon tetrachloride by inhalation  
  CCl4ORAL  carbon tetrachloride by oral gavage  
  Col1a1   alpha‐1 type I collagen  
  CTRL   control  
  Enos or eNOS   endothelial nitric‐oxide synthase  
  IL‐6   interleukin 6  
  L‐NMMA   NG‐Methyl‐L‐arginine acetate salt  
  SD   Sprague‐Dawley rats  
  SNAP   S‐Nitroso‐N‐acetyl‐DL‐penicillamine  
  Timp1   TIMP metallopeptidase inhibitor 1  
  Vegfa   vascular endothelial growth factor A  
KEY POINTS 
 Anticoagulation has been proposed to have antifibrogenic effects and to attenuate portal hypertension‐related 
complications in mild‐to‐moderate liver disease. 
 We evaluated several doses and protocols of enoxaparin administration in three different models of advanced 
cirrhosis in rats. 
 Enoxaparin administration failed to ameliorate liver function, liver fibrosis, profibrogenic gene expression, portal 
hypertension, splenomegaly, ascites development and infection, serum IL‐6 levels, hepatic endothelial dysfunction 
or survival. 
 Beneficial effects of enoxaparin may be lost or become even detrimental at late stages of advanced liver disease. 
The possibility of a limited therapeutic window should be considered in future studies. 
INTRODUCTION 
The traditional concept of cirrhosis as the terminal stage of chronic liver disease has gradually changed 
to its view as an entity comprising progressive phases with distinct prognosis and therapeutic 
opportunities, which include the use of anticoagulants.1 Indeed, cirrhosis is no longer considered a 
bleeding disorder, but rather a disease with a delicate equilibrium between prothrombotic and 
prohaemorrhagic profiles that may be unbalanced towards the former, leading to thrombotic 
manifestations such as portal vein thrombosis.2 Importantly, prothrombotic states may also contribute 
to liver fibrosis by generating thrombi in the hepatic microcirculation that cause parenchymal 
extinction and by activating hepatic stellate cells via protease‐activated receptors.3, 4 Consequently, 
the use of enoxaparin at prophylactic doses (4000 IU/day for 48 weeks) vs no treatment was recently 
tested by Villa et al. in 70 patients with cirrhosis (Child B7‐C10).5 Patients receiving enoxaparin had 
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lower incidence of portal vein thrombosis and a sustained decrease in decompensations that exceeded 
the expected from the reduction in portal vein thrombosis. The authors hinted at an enoxaparin‐induced 
improvement of intestinal barrier function and reduced bacterial translocation as a potential 
mechanism.  
Low molecular weight heparins have mechanisms besides their anticoagulant effect that may be 
beneficial in cirrhosis. Several studies have reported anti‐inflammatory 6 and anti‐angiogenic effects,7 
and improvements of endothelial cell function by low molecular weight heparins.8 In addition, 
antifibrotic effects of heparins were suggested in patients with chronic hepatitis B.9 Low molecular 
weight heparins have been reported to reduce liver fibrosis, stellate cell activation, and hepatocyte 
apoptosis/necrosis in toxic and surgical rodent models of cirrhosis.10-13 Recently, remarkable 
attenuations of stellate cell activation and fibrin sinusoidal deposition together with reductions in liver 
fibrosis and portal hypertension were described in cirrhotic rats treated with enoxaparin.14 Importantly, 
all prior experimental studies involved models of early fibrosis or cirrhosis regression, and evaluated 
only high enoxaparin doses (≥180 IU/Kg/day) in contrast to the prophylactic dose (40‐60 IU/Kg/day) 
used clinically.5, 9 In addition, mechanisms of enoxaparin other than direct antifibrogenic effects or 
effects on the intestinal epithelial barrier remain unexplored in cirrhosis.  
Here, we evaluated the effects of enoxaparin on liver fibrosis, portal hypertension and vascular 
endothelial cell dysfunction using diverse protocols of enoxaparin administration and several 
experimental models of advanced cirrhosis in rats. 
MATERIAL AND METHODS 
ANIMALS AND EXPERIMENTAL MODELS OF CIRRHOSIS 
All experiments were performed in male Sprague‐Dawley (SD) rats (Charles River Laboratories). The 
studies were approved by the Comité de Ética en Experimentación Animal of HGU Gregorio Marañón, 
the Institutional Animal Protection Committee of CRCHUM and the Landesverwaltungsamt Sachsen‐
Anhalt of Martin‐Luther‐Universität Halle‐Wittenberg. Rats were housed in temperature‐ and 
humidity‐controlled rooms, with a 12:12 h light:dark cycle, free access to standard chow and water and 
a 7‐10 days acclimatization period. We used several regimes of enoxaparin administration (Clexane 
prefilled syringes®, SANOFI‐AVENTIS France) and three experimental models of cirrhosis 
(Figure 1A).  
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Figure 1 (A) Schematic of experimental design and protocols of enoxaparin administration. Abbreviations: BDL, bile‐duct 
ligation; CCl4, carbon tetrachloride; wk, week. (B) Quantification of anti‐Xa activity in arterial blood collected 30 minutes 
after an intravenous injection of sterile 0.9% saline (SAL), enoxaparin 40 IU/Kg (Enox40), or enoxaparin 180 IU/Kg 
(Enox180) in rats. The dots and group lines represent the value from individual rats and the median, respectively. The 
dashed line represents the lower limit of the prophylactic range of enoxaparin, and the darker area represents its therapeutic 
anticoagulation range. *P < .05, ****P < .0001 (ANOVA with Tukey's post hoc tests)  
EXPERIMENT A. CIRRHOSIS INDUCED BY ADMINISTRATION OF CCL4 BY ORAL GAVAGE 
Experiments were performed at the HGU Gregorio Marañón (Madrid, Spain). Cirrhosis was induced in 
male SD rats (130‐200 g bw) by the administration of CCl4 based on the protocol by Regimbeau 
et al.15 Briefly, phenobarbital (0.35 g/l) was added to the drinking water 2 weeks before starting CCl4 
administration (99.9% pure, Sigma‐Aldrich) until the day of euthanasia. CCl4 was administered 
biweekly (Monday and Friday) by oral gavage for 12 weeks, with the dose adjusted to the body weight 
(BW) of the rat on that same day. Rats in control groups (CTRL) received 0.5 mL of water instead of 
CCl4. All rats received enoxaparin (40 IU/Kg/day s.c. [Enox40 groups] or 180 IU/Kg/day s.c. 
[Enox180 groups]) or saline (Sal, 0.5 mL/day s.c.) from the 8th week of CCl4 administration until the 
end of experiments (Figure 1A). We studied the following experimental groups: CTRL+Sal (n = 5), 
CTRL+Enox40 (n = 5), CTRL+Enox180 (n = 3), CCl4ORAL+Sal (n = 15), CCl4ORAL+Enox40 (n = 15), 
and CCl4ORAL+Enox180 (n = 10). Three rats in the CCl4ORAL+Sal and CCl4ORAL+Enox180 groups, and 
two CCl4ORAL+Enox40 rats were excluded owing to death related to technical complications of oral 
gavage. A haemodynamic study was performed 2 weeks after the last CCl4 dose.  
EXPERIMENT B. CIRRHOSIS INDUCED BY COMMON BILE‐DUCT LIGATION (BDL) 
Experiments were performed at the Hepato‐Neuro Laboratory of CRCHUM‐Université de Montréal 
(Montreal, QC, Canada). Male SD rats (250 g bw) underwent BDL or sham surgery as previously 
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described.16 Briefly, the abdomen was opened, formalin (1 μL/mg) was injected intracholedochally, 
and the common bile duct was ligated and cut. In the Sham group, the common bile duct was only 
manipulated. One week later, enoxaparin (180 IU/Kg/day) or saline (0.5 mL/day) was given s.c. for 
4 weeks (Figure 1A). Four groups were studied: Sham+Sal (n = 6), Sham+Enox180 (n = 6), BDL+Sal 
(n = 7) and BDL+Enox180 (n = 10). Rats underwent a haemodynamic study on the 5th week.  
EXPERIMENT C. CIRRHOSIS INDUCED BY INHALATION OF CCL4 
Experiments were performed at Martin‐Luther‐Universität Halle‐Wittenberg (Halle, Germany). Male 
SD rats (75‐100 g bw) were exposed to gaseous CCl4 three times a week in a fume hood for 8 or 
12 weeks (Figure 1A). Phenobarbital (0.35 g/l) was added to the drinking water as previously 
described.17 In experiment C.1, saline (0.5 mL/day s.c, CCl4INH + Sal group, n = 22) or enoxaparin 
(180 IU/Kg/day s.c, CCl4INH + Enox180 group, n = 29) was administered from the first day of CCl4 
exposure until the performance of the liver perfusions in the 8th week of treatment. In experiment C.2, 
saline (0.5 mL/day s.c, n = 18) or enoxaparin (40 IU/Kg/day s.c, CCl4INH +Enox40 group, n = 20) was 
injected from the 8th week of CCl4 administration until the performance of the in situ liver perfusions.  
MEASUREMENT OF ANTI‐XA ACTIVITY 
SD rats (n = 5‐6/group) were i.v. injected 0.9% saline, enoxaparin 40 IU/Kg or enoxaparin 180 IU/Kg 
under sevoflurane anaesthesia. Thirty minutes later, blood from the aorta was collected in citrate‐
containing tubes. Anti‐Xa activity was measured using Liquid Anti‐Xa (Cat#20302600, HemosIL® 
Instrumentation Laboratory, Germany).  
HAEMATOLOGICAL AND BIOCHEMICAL BLOOD TESTS 
Arterial blood was obtained just before euthanasia. Blood cell counts, arterial blood gases, coagulation 
and biochemical parameters were measured in automated analysers. Serum aliquots were stored at 
−80°C. 
MICROBIOLOGICAL STUDY OF ASCITES 
An ascites sample obtained under sterile conditions immediately after opening the abdomen was 
inoculated into thioglycolate‐containing tubes. After a 3‐day incubation at 37°C, the tubes were 
examined for bacterial growth. 
CIRCULATING CONCENTRATION OF INTERLEUKIN (IL)‐6 
The concentration of IL‐6 was measured in serum from arterial blood using a commercially available 
rat IL‐6 ELISA kit (BD Biosciences). 
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HAEMODYNAMIC STUDY, HISTOLOGY AND QUANTIFICATION OF FIBROSIS, HEPATIC MRNA AND PROTEIN 
EXPRESSION OF FIBROSIS‐ AND ENDOTHELIUM‐RELATED GENES 
See Supporting Information for detailed descriptions. 
EX VIVO ASSESSMENT OF MICROCIRCULATORY DYSFUNCTION OF HEPATIC VASCULAR BED 
The perfusion experiments were done 6‐10 days after the last CCl4 dose using two different set‐ups, 
consisting of a single portal vein perfusion and a bivascular liver perfusion, as previously described.17, 
18 See Supporting Information for further details.  
STATISTICAL ANALYSIS 
Quantitative variables were expressed as mean ± SEM or median[interquartile range], and qualitative 
variables as proportions. For each model, all control rats (receiving water instead of CCl4, or sham 
surgery instead of BDL) were pooled to gain statistical power and to comply with the three Rs 
principle. Control rats receiving enoxaparin remained identified by distinct symbols in graphs. 
Analyses without pooling only showed minor changes without interference on the comparisons 
between cirrhotic rats treated or not‐treated with enoxaparin. Differences between groups were 
assessed by ANOVA with Tukey's post hoc tests or by the Kruskal‐Wallis test with Dunn's tests. 
Supplementary Table 1 in Supporting Information contains the P values corresponding to post hoc 
comparisons between cirrhotic rats treated or not treated with enoxaparin. Proportions were compared 
with the Fisher's exact test. Survival was analysed using the Log‐rank Test, applying the Bonferroni's 
correction of p for post hoc multiple comparisons (0.05/6 = 0.0083). The liver perfusion experiments 
were analysed by General Linear Model for Repeated Measurements, followed by LSD post hoc test 
when comparisons included more than two groups. P < .05 was statistically significant. Software used 
was Prism v6.00 (GraphPad‐Software, San Diego, CA, USA) and IBM SPSS‐Statistics v21 (IBM 
Corp, Armonk, NY, USA).  
RESULTS 
ENOXAPARIN DOSES AND ANTI‐XA ACTIVITY 
The doses of enoxaparin used in this study adequately targeted the prophylactic (0.2 to 0.5 IU/mL) and 
therapeutic (0.5 to 1.2 IU/mL) ranges of anti‐Xa activity (Figure 1B).  
SURVIVAL 
In the oral CCl4 model, the survival in the Pooled Controls, the CCl4ORAL+Sal, the CCl4ORAL + Enox40 
and the CCl4ORAL + Enox180 groups was, respectively, 100%, 82.5%, 67.7% and 38.1% (Log‐rank test 
P = .02; Pooled CTRLs vs CCl4ORAL+Enox180 group P = .002, Figure 2). Only two 
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CCl4ORAL+Enox180 rats were alive at the end of the 12‐week protocol and, therefore, this group was 
not included in further analyses. Mortality in rats receiving CCl4 was generally preceded by weight 
loss and progressive deterioration related to liver disease, with no evidence of bleeding in any group.  
 
Figure 2 Effect of enoxaparin on survival of rats with cirrhosis induced by CCl4 administered by oral gavage. The groups 
of rats receiving water instead of CCl4 that were treated with saline or enoxaparin were pooled in a single control group 
(Pooled CTRLs). The graph shows Kaplan‐Meier survival curves. The gray box represents the period of administration of 
saline or enoxaparin. The Log‐rank Test was used to compare the survival curves of all groups (P = .020). Post hoc multiple 
comparisons with Bonferroni's correction showed P = .002 for Pooled CTRLs vs CCl4ORAL+Enox180. Abbreviations: 
CCl4ORAL, carbon tetrachloride administered by oral gavage; Enox40, enoxaparin 40 IU/Kg/day s.c; Enox180, enoxaparin 
180 IU/Kg/day s.c; Sal, 0.9% saline s.c.  
In the BDL experimental model, survival at week 5 was excellent in all groups with only one rat of the 
BDL+Enox180 group dying earlier (Pooled Shams: 100% vs BDL+Sal: 100% vs BDL+Enox180: 90%, 
NS). 
HAEMATOLOGICAL AND BIOCHEMICAL BLOOD TESTS 
Blood tests were similarly altered in the CCl4ORAL+Sal and CCl4ORAL+Enox40 groups compared with 
controls (Table 1). Both groups of rats receiving CCl4 developed leukocytosis, thrombocytopenia, 
lower glycaemia, hypertransaminasemia and similar deterioration of parameters reflecting liver 
function (INR, total bilirubin and albumin). The decrease in fibrinogen level was significant only in the 
CCl4ORAL + Enox40 group. Arterial blood gases and kidney function parameters were normal in all 
groups, except for a slight increase in potassium in CCl4 rats (Supplementary Table 2).  
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Table 1. Haematological and blood biochemical parameters  
 Oral CCl4 model BDL model 
Pooled 
CTRLs 









13.0 [11.8, 14.5]    
White blood cells 





6.6 [5.3, 15.1]**    
Platelets 





357 [153, 637]**    




120 [102, 141]**    
ALT (U/L) 28 [25, 37] 68 [54, 89]** 97 [77, 107]*** 33 [23, 40] 28 [17, 38] 45 [31, 56] 
INR 1.2 [1.1, 
1.2] 




1.8 [0.9, 1.8] 
Fibrinogen (mg/dL) 211 [194, 
225] 









3.2 [1.2, 4.8]* 
Albumin (g/dL) 3.5 [3.5, 
3.7] 
2.5 [1.9, 2.7]** 2.2 [2.1, 2.4]***    
*P < .05 vs Pooled CTRLs or Pooled SHAMs, **P < .01 vs Pooled CTRLs or Pooled SHAMs, ***P < .001 vs. 
Pooled CTRLs.  
The BDL+Sal and BDL+Enox180 groups developed increases in total bilirubin in blood compared with 
Sham‐operated rats, but only the BDL+Sal group showed a significant increase in INR (P = .0096) 
(Table 1). All BDL groups showed normal ALT levels.  
LIVER FIBROSIS 
Administration of CCl4ORAL led to consistent development of fibrosis and macro‐micro nodular 
cirrhosis regardless of enoxaparin treatment (Figure 3A‐D). Compared with the Pooled CTRLs group 
[0.7% (0.6, 1.2)], the area of liver fibrosis was similarly increased in the CCl4ORAL+Sal [15.9% (12.0, 
17.8), P < .01] and CCl4ORAL + Enox40 [17.4% (16.2, 20.6), P < .001] groups, as assessed by the Sirius 
Red staining (Figure 3A). Similar results were obtained with the Masson's Trichrome staining [Pooled 
CTRLs: 0.22% (0.12, 0.34), vs CCl4ORAL+Sal: 3.99% (2.70, 4.63) and CCl4ORAL+Enox40: 5.08% 
(4.30, 8.06), P < .01 and P < .001 respectively].  
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Figure 3 Effect of enoxaparin on liver fibrosis in rats with cirrhosis induced by oral gavage with CCl4 (CCl4ORAL) or by 
bile duct ligation (BDL). (A) Quantification of the area of fibrosis (%) in Sirius Red stained liver sections. The line and dots 
represent the median and individual rat values respectively. **P < .01, ***P < .001 (Kruskal‐Wallis with Dunn's post hoc 
tests). (B‐F) Representative pictures of Sirius Red stained liver sections from a control rat receiving oral gavage with water 
(B), a rat with cirrhosis induced by oral gavage with CCl4 treated with saline (C) or with enoxaparin 40 IU/Kg/day s.c. from 
week 8 of CCl4 (D) and a rat with cirrhosis induced by BDL treated with saline (E) or enoxaparin 180 IU/Kg/day from 
week 1 after the surgery (F)  
Rats undergoing BDL developed biliary cirrhosis with extensive bile‐duct proliferation and periductal 
fibrosis regardless of enoxaparin treatment (Figure 3E‐F). Compared with the Pooled SHAMs group 
[1.0% (0.7, 1.3)], the area of fibrosis was similarly increased in the BDL+Sal [8.7% (6.0, 14.1), 
P < .01] and the BDL+Enox180 [11.4% (7.9, 17.1), P < .001] groups, as assessed by Sirius Red 
staining (Figure 3A).  
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The expression of Col1a1, Acta2 and Timp1 mRNAs was markedly induced in the liver of cirrhotic 
rats, but enoxaparin had no influence neither in the CCl4ORAL nor the BDL models (Figure 4A‐C). 
Likewise, the protein expression of platelet‐derived growth factor receptor‐β and α‐smooth muscle 
actin was similarly increased in the liver of CCL4ORAL rats regardless of enoxaparin treatment 
(Figure 4D).  
 
Figure 4 Effect of enoxaparin on the expression of fibrosis‐related genes and proteins. The graphs show the mRNA 
expression of (A) collagen 1‐alpha (Col1a1), (B) alpha‐smooth muscle actin (Acta2) and (C) TIMP metallopeptidase 
inhibitor 1 (Timp1) in liver tissue from rats with cirrhosis induced by oral gavage with CCl4 (CCl4ORAL) or by bile duct 
ligation (BDL). (D) Representative Western blots of platelet‐derived growth factor receptor‐β (PDGFR‐b), α‐smooth muscle 
actin (a‐SMA), and glyceraldehyde‐3‐phosphate dehydrogenase (GAPDH) in livers from CCl4ORAL rats and their controls, 
with (E) their corresponding densitometric analyses. In each experimental model, rats treated with saline or enoxaparin that 
received oral gavage with water (Pooled CTRLs) or sham surgery (Pooled SHAMs) were pooled. Enoxaparin dose was 
40 IU/Kg/day in the CCl4ORAL model and 180 IU/Kg/day in the BDL model. The line and dots represent the median and 
individual rat values, respectively. *P < .05, **P < .01, ***P < .001 (Kruskal‐Wallis with Dunn's post hoc tests)  
DEVELOPMENT OF PORTAL HYPERTENSION 
Enoxaparin did not prevent the development of ascites in rats receiving CCl4 (CCl4ORAL+Sal: 80% vs 
CCl4ORAL+Enox40: 100%, P = .47) or in BDL rats (BDL+Sal: 86% vs BDL+Enox180: 70%, P = .60). 
None of the control rats had ascites.  
Enoxaparin administration had no relevant effects on heart rate, mean arterial pressure or respiratory 
rate in any of the experimental models, although heart rates were decreased in BDL groups compared 
with the SHAM+Enox180 group (Supplementary Table 3). Rats with CCl4‐induced cirrhosis showed 
marked increases in portal pressure [Pooled CTRLs: 6.07 mmHg (5.11, 7.35), CCl4ORAL+Sal: 
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14.47 mmHg (14.03, 16.16), CCl4ORAL+Enox40: 12.43 mmHg (11.11, 15.03), ANOVA P < .0001] and 
of the spleen‐to‐BW ratio [Pooled CTRLs: 0.165% (0.158, 0.190), CCl4ORAL+Sal: 0.430% (0.345, 
0.485), CCl4ORAL+Enox40: 0.470% (0.375, 0.505), Kruskal‐Wallis test P < .0001], none of which was 
influenced by enoxaparin treatment (Figure 5A,B). Similarly, BDL rats also developed increases in 
portal pressure [Pooled Shams: 6.15 mmHg (5.03, 7.38), BDL+Sal: 11.50 mmHg (9.50, 14.50), 
BDL+Enox180: 15.68 mmHg (13.62, 16.73), ANOVA P < .0001] and of the spleen‐to‐BW ratio 
[Pooled Shams: 0.195% (0.168, 0.200), BDL+Sal: 0.735% (0.700, 0.793), BDL+Enox180: 0.660% 
(0.570, 0.930), Kruskal‐Wallis test P<  0 .01) with respect to the Pooled Shams group (Figure 5A,B). 
Of note, enoxaparin worsened portal hypertension in BDL rats (P < .05 BDL + Sal vs 
BDL + Enox180).  
 
Figure 5 Effect of enoxaparin on the development of portal hypertension in rats with cirrhosis induced by oral gavage with 
CCl4 (CCl4ORAL) or by bile duct ligation (BDL). The graphs show (A) portal pressure values and (B) spleen‐to‐body weight 
ratios in individual rats. In each experimental model, control rats treated with saline or enoxaparin that received oral gavage 
with water (Pooled CTRLs) or sham surgery (Pooled SHAMs) were pooled. Enoxaparin dose was 40 IU/Kg/day in the 
CCl4ORAL model and 180 IU/Kg/day in the BDL model. The line and dots represent the median and individual rat values. 
*P < .05, **P < .01, ***P < .001 (Kruskal‐Wallis with Dunn's post hoc tests)  
To assess for subtler effects of enoxaparin on the hepatic vascular endothelium, we evaluated the 
expression of endothelial nitric‐oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) 
in liver tissue (Figure 6A‐D). The mRNA and protein expression of eNOS were not affected by the 
development of cirrhosis or by enoxaparin treatment in the CCl4 model, although some rats receiving 
enoxaparin showed marked up‐regulation of Enos mRNA. No significant changes in Enos mRNA 
expression were observed in BDL rats. Compared with controls, the Vegfa mRNA expression was 
decreased in cirrhotic rats regardless of enoxaparin administration both in the CCl4ORAL and the BDL 
models (Figure 6B). In contrast, the protein expression of VEGF was increased in the livers of 
CCl4ORAL rats (P < .05) regardless of enoxaparin treatment (Figure 6C,D).  
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Figure 6 Effect of enoxaparin on the expression of endothelium‐related genes and proteins. The graphs show the mRNA 
expression of (A) endothelial nitric‐oxide synthase (eNOS), and (B) vascular endothelial growth factor A (Vegfa) in liver 
tissue from rats with cirrhosis induced by oral gavage with CCl4 (CCl4ORAL) or by bile duct ligation (BDL). (C) 
Representative Western blots of eNOS and vascular endothelial growth factor (VEGF) in livers from CCl4ORAL rats and 
their controls, with (D) their corresponding densitometric analyses. In each experimental model, rats treated with saline or 
enoxaparin that received oral gavage with water (Pooled CTRLs) or sham surgery (Pooled SHAMs) were pooled. 
Enoxaparin dose was 40 IU/Kg/day in the CCl4ORAL model and 180 IU/Kg/day in the BDL model. The line and dots 
represent the median and individual rat values respectively. *P < .05, **P < .01, ***P < .001 (Kruskal‐Wallis with Dunn's 
post hoc tests)  
BACTERIAL TRANSLOCATION AND SYSTEMIC INFLAMMATION 
Among rats with ascites, the proportion that presented positive bacterial cultures of ascites were similar 
in the CCl4ORAL+Sal and CCl4ORAL+Enox40 groups [2 of 7 (28.6%) vs 4 of 8 (50%), P = .61]. Both 
groups also had similar levels of circulating IL‐6 (349 ± 138 pg/mL vs 248 ± pg/mL, P = .89).  
Among BDL rats with ascites, the proportion of rats with positive bacterial cultures was also similar in 
the BDL+Sal and BDL+Enox180 groups [1 of 6 (16.7%) vs 2 of 7 (28.6%), P = 1.0]. The circulating 
levels of IL‐6 were also similar in both groups (278 ± 103 pg/mL vs 370 ± 168 pg/mL, P = .94).  
CIRRHOSIS‐ASSOCIATED MICROCIRCULATORY DYSFUNCTION OF HEPATIC VASCULAR BED 
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To assess the effects of enoxaparin on the hepatic microcirculation, we performed in situ liver 
perfusion experiments in rats with cirrhosis induced by CCl4INH (Figure 1, experiments C.1 and C.2). 
In these experiments, survival of rats treated with saline or enoxaparin was, respectively, 91.2% (31 of 
34) and 94.4% (34 of 36) in those with 8 weeks of CCl4 inhalation (P = .67), and 74.1% (20 of 27) and 
57.6% (19 of 33) in those with 12 weeks of CCl4 inhalation (P = .28).  
In rats with 8 weeks of CCl4 inhalation (experiment C.1), the absolute values of portal venous 
resistance were higher in enoxaparin‐treated than in saline‐treated rats at baseline and at all 
concentrations of acetylcholine (P = .048) and S‐Nitroso‐N‐acetyl‐DL‐penicillamine (SNAP, P = .005) 
tested (Figure 7A,B). The percent changes in portal venous resistance from methoxamine‐induced 
preconstriction, however, were virtually identical in saline‐ and enoxaparin‐treated rats in response to 
acetylcholine (P = .35) and to SNAP (P = .45) (Supplementary Figure 1A,B). Similarly, the absolute 
values of sinusoidal resistance were higher in enoxaparin‐treated rats at all concentrations of SNAP 
tested (P = .027), but not of acetylcholine (P = .26) (Figure 7C,D). The percent reduction in sinusoidal 
resistance from methoxamine‐induced preconstriction was similar in both groups in response to 
acetylcholine (P = .076) and to SNAP (P = .41) (Supplementary Figure 1 C,D). Noteworthy, the area of 
liver fibrosis (Sirius Red staining) was increased in enoxaparin‐treated rats [CCl4INH+Sal: 10.7% (7.6, 
13.6) vs CCl4INH+Enox180: 20.7% (11.0, 22.2), P = .029] (Supplementary Figure 2).  
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Figure 7 Effect of enoxaparin on the portal vascular bed reactivity (A‐D) and on the hepatic arterial vascular resistance (E) 
assessed by in situ liver perfusions in rats with cirrhosis induced by 8 weeks of CCl4 inhalation (CCl4INH). Absolute values 
of (A, B) portal venous resistance and (C, D) sinusoidal resistance in response to increasing concentrations of acetylcholine 
(ACH) and S‐Nitroso‐N‐acetyl‐DL‐penicillamine (SNAP). Groups were compared by a General Linear Model for Repeated 
Measurements. (E) Absolute values of hepatic arterial vascular resistance in response to increasing concentrations of 
methoxamine in the presence or absence of L‐NMMA. Groups were compared by a General Linear Model for Repeated 
Measurements (P = .074), followed by LSD post hoc tests (CCl4‐Sal vs CCl4‐Sal+LNMMA P = .036, CCl4‐Enox180 vs 
CCl4‐Enox180+LNMMA P = .67, CCl4‐Sal vs CCl4‐Enox180 P = .025, CCl4‐Sal+LNMMA vs CCl4‐Enox180+LNMMA 
P = .45). Rats were treated with saline (Sal) or enoxaparin (180 IU/Kg/day, Enox180) for the full period of CCl4 
administration. Abbreviations: B, baseline; MTX, preconstriction with methoxamine  
Regarding the hepatic artery, cirrhotic rats treated with saline showed lower hepatic arterial vascular 
resistances and an upward shift of the curve in response to methoxamine when NG‐Methyl‐L‐arginine 
acetate salt (L‐NMMA), an inhibitor of nitric oxide synthesis, was added to the perfusion fluid, 
reflecting the characteristic dysfunction (nitric‐oxide overproduction) of the hepatic artery in cirrhosis 
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(CCl4INH + Sal vs CCl4IHN + Sal + L‐NMMA, P = .036). Such feature, however, was not observed in 
cirrhotic rats treated with enoxaparin (CCl4INH+Enox180 vs. CCl4IHN+Enox180+L‐NMMA, P = .67) 
(Figure 7E).  
In rats with more prolonged CCl4 exposure and low‐dose enoxaparin (experiment C.2), the absolute 
values and the percent changes in the portal venous and sinusoidal resistance curves in response to 
acetylcholine and SNAP, as well as the hepatic arterial dysfunction characteristic of cirrhosis, were 
similar in saline‐ and enoxaparin‐treated rats (Supplementary Figures 3 and 4). 
DISCUSSION 
Based on promising clinical and experimental observations, anticoagulants are attracting attention as a 
potential routine medication for patients with liver disease. In this study, however, several protocols of 
enoxaparin administration in a variety of experimental models of advanced cirrhosis in rats consistently 
failed to show the expected protective effects against liver fibrosis, portal hypertension and hepatic 
endothelial dysfunction. Biochemical parameters of liver function were not improved either. Although 
we noted some beneficial effects of enoxaparin, they were mostly marginal. Unsettlingly, we also 
observed pernicious effects of enoxaparin scattered across the diverse models, including decreased 
survival in CCl4ORAL+Enox180 rats, increased portal venous resistance and liver fibrosis in 
CCl4INH+Enox180 rats, or worsening portal hypertension in BDL+Enox180 rats. Remarkably, the 
different experimental models (CCl4ORAL, BDL, CCl4INH) were performed in three independent 
laboratories with expertise in each of them, but all coincided in the lack of conclusive benefits from 
enoxaparin. Collectively, our results suggest that the potential benefits of enoxaparin administration are 
largely diminished or lost at late stages of advanced cirrhosis. Those stages, however, are where 
therapies to influence the natural history of the disease are most needed.  
The inability of enoxaparin to ameliorate liver fibrosis or the hepatic expression of profibrogenic genes 
reflecting hepatic stellate cell activation was a consistent observation in our study. These results differ 
from previous experimental studies reporting a protective effect of anticoagulants against liver 
fibrosis.10-13 Importantly, most of our protocols involved the initiation of enoxaparin once that 
cirrhosis was fully established and its continuation throughout late stages of advanced cirrhosis, 
whereas most prior studies started anticoagulation before the initiation of the hepatic insult or limited 
the evaluation to early stages of disease.10-13 Noteworthy, the reduction in liver fibrosis was generally 
modest in all prior studies, intragroup variability was higher than ours, and some low molecular weight 
heparins had no effect or even deleterious effects.10 Relevant methodological differences also exist 
with the study by Cerini et al., in which the effect on the extent of fibrosis was also modest:14 (a) their 
study involved a shorter administration of enoxaparin (3 weeks vs up to 7 weeks) that started in most 
cases 1 week after the discontinuation of CCl4 or thioacetamide, resembling a paradigm of cirrhosis 
regression rather than progression, (b) the intrahepatic vascular resistance was evaluated in vivo (vs in 
situ), (c) the rats were younger (50‐75 vs 150‐200 g bw) and (d) the extent of fibrosis and the degree of 
portal hypertension suggested less advanced disease. Therefore, major differences in experimental 
designs and methodology possibly explain the apparent contradictions with prior studies.  
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The vascular endothelium is a major site of action for heparin in the rat and other mammals,19 
although discordant effects of heparins have been reported regarding the modulation of vascular tone or 
endothelial‐related genes.20-24 In our study, enoxaparin seemed to induce Enos expression in some 
individual rats, but overall eNOS mRNA and protein expression remained unchanged. Although 
cirrhosis was associated with changes in the expression of VEGF in liver tissue, such changes were not 
affected by enoxaparin either. In a recent study, rats receiving enoxaparin showed a reduction in portal 
hypertension related to a decrease in intrahepatic vascular resistance, which was explained by a 
reduction in liver fibrosis rather than by an improvement of endothelial cell function.14 Here, we 
performed a detailed examination using in vivo measurements of systemic and hepatic haemodynamics 
and in‐situ liver perfusion experiments to specifically assess endothelial dysfunction in the portal 
venous and hepatic arterial vascular beds. As in the prior study,14 enoxaparin did not influence 
systemic haemodynamic parameters such as mean arterial pressure or heart rate. However, we did not 
observe an attenuation of portal hypertension by enoxaparin in rats with CCl4‐ or BDL‐induced 
cirrhosis, as assessed by its direct measurement or by indirect markers such as the development of 
splenomegaly and ascites. On the contrary, enoxaparin was even associated with worsening of portal 
hypertension in BDL rats. Such observations were supported by the in situ liver perfusion experiments, 
in which the percent changes in portal venous resistance and sinusoidal resistance were almost identical 
in saline‐ and enoxaparin‐treated rats. The increased absolute values of portal venous and sinusoidal 
resistance at all tested concentrations of vasodilators in enoxaparin‐treated rats (experiment C.1) 
suggested worsening of an underlying static factor, likely related to the increased fibrosis of those 
livers. Although the high dose of enoxaparin corrected the endothelial dysfunction in the hepatic artery 
when it was administered in parallel with CCl4 (early cirrhosis, experiment C.1), such an effect was not 
observed when a prophylactic dose was started in rats with advanced cirrhosis (experiment C.2).  
Consistent with the lack of effects on liver fibrosis and haemodynamics, enoxaparin influenced neither 
systemic inflammation nor bacterial translocation, two purported mechanisms of action. Prior studies 
showing increased anti‐Xa activity in cirrhotic rats treated with 180 IU/Kg/day of enoxaparin 14 
together with our results of anti‐Xa activity make unlikely that the ineffectiveness of enoxaparin was 
caused by a lack of target engagement. It is conceivable that highly cross‐linked collagen fibres and 
fibrotic acellular septa in advanced cirrhosis are not susceptible to potential antifibrotic effects of 
enoxaparin. Changes in intrahepatic inflammation or microthrombus formation could underlie 
deleterious effects of enoxaparin observed in our study. Heparin and low molecular weight heparins 
have been occasionally reported to increase platelet activation and aggregation,25 and to promote a 
prothrombotic state shortly after its withdrawal in patients with unstable angina.26 In this regard, 
altered pharmacokinetics and/or pharmacodynamics of enoxaparin at advanced stages of liver disease 
should also be considered.  
The increased mortality in CCl4ORAL+Enox180 rats appeared to obey to a more advanced liver disease, 
as no haemorrhagic complications were noted. Although mortality also tended to be higher in CCl4INH 
rats treated with enoxaparin compared with saline, the difference was not significant (42.4% vs 25.9%, 
P = .28). To our knowledge, there are no potential interactions between enoxaparin and carbon 
tetrachloride or cytochrome P450 metabolism that could explain the increased mortality.  
This is the peer reviewed version of the following article: Fortea, J. I.; Zipprich, A.; Fernandez-Mena, C.; Puerto, M.; Bosoi, C. R.; 
Almagro, J.; Hollenbach, M.; Bañares, J.; Rodríguez-Sánchez, B.; Cercenado, E.; Clément, M.-A.; Rose, C. F.; Bañares, R.; Vaquero, J. 
& Ripoll, C. Enoxaparin does not ameliorate liver fibrosis or portal hypertension in rats with advanced cirrhosis. Liver international 2018, 
38, 102-112, which has been published in final form at 10.1111/liv.13510. This article may be used for non-commercial purposes in 
accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. 
Fortea, J. I.; Zipprich, A.; Fernandez-Mena, C.; Puerto, M.; Bosoi, C. R.; Almagro, J.; Hollenbach, M.; Bañares, J.; Rodríguez-Sánchez, 
B.; Cercenado, E.; Clément, M.-A.; Rose, C. F.; Bañares, R.; Vaquero, J. & Ripoll, C. Enoxaparin does not ameliorate liver fibrosis or 
portal hypertension in rats with advanced cirrhosis. Liver international 2018, 38, 102-112 
In conclusion, our results suggest that the beneficial effects of enoxaparin are lost or may even be 
detrimental at late stages of advanced liver disease or when the hepatic insult is ongoing. These factors 
and the possibility of a limited therapeutic window should be considered in clinical and experimental 
studies of anticoagulants in liver disease. 
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